Gene Therapy for PARKIN-PD
Parkinson's Disease (Parkin mutation-associated)
PreclinicalActive
Key Facts
Indication
Parkinson's Disease (Parkin mutation-associated)
Phase
Preclinical
Status
Active
Company
About NysnoBio
NysnoBio is a private, preclinical-stage biotech developing a novel gene therapy platform centered on the Parkin enzyme, a key regulator of mitochondrial health. The company's lead program targets Parkin-associated Parkinson's disease (PARKIN-PD), a genetically defined subset with high penetrance, with the goal of delivering a one-time, disease-modifying treatment. Leveraging deep scientific expertise in Parkin biology and AAV gene therapy, NysnoBio is positioned to address a significant unmet need in neurodegenerative diseases and potentially expand to broader idiopathic Parkinson's populations. The company is currently in IND-enabling studies.
View full company profile